FDA promotions watchdog delivers first warning letter of the year to AstraZeneca over Breztri marketing
15 Aug 2023
AstraZeneca has received the first warning letter of the year from the FDA’s promotion police over alleged efficacy claims for its COPD med Breztri Aerosphere. The warning is only the second letter of the year from FDA’s promo office, following an untitled letter in June to Xeris Pharmaceuticals for its Cushing’s syndrome drug Recorlev.
The Office of Prescription Drug Promotion (OPDP) sent the AstraZeneca warning letter – the more serious of the two types of enforcement notices – regarding a Breztri “professional sales aid” during the first week of August.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.